Evidence map›Paper›PMID 27249364›Full record

ArticleNature communications2016

Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice.

V Beglopoulos, J Tulloch, A D Roe, S Daumas, L Ferrington, R Watson, Z Fan, B T Hyman, P A T Kelly, F Bard and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

V BeglopoulosCentre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
J TullochCentre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
A D RoeDepartment of Neurology, Mass General Institute for Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA.
S DaumasNeuroscience Paris Seine, Institut de Biologie Paris Seine, Sorbonne Universités, Pierre and Marie Curie University, UM CR18, INSERM U1130, CNRS UMR 8246, 75005 Paris, France.
L FerringtonCentre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
R WatsonCentre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
Z FanDepartment of Neurology, Mass General Institute for Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA.
B T HymanDepartment of Neurology, Mass General Institute for Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA.
P A T KellyCentre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.
F BardJanssen Prevention Center, Janssen Pharmaceutical Companies of Johnson &Johnson, 3210 Merryfield Row, San Diego, California 92121, USA.
R G M MorrisCentre for Cognitive and Neural Systems, Edinburgh Neuroscience, The University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK.

Funding

Medical Research Council G0700447
6 · The paper itself

Abstract

Earlier diagnosis and treatment of Alzheimer's disease would greatly benefit from the identification of biomarkers at the prodromal stage. Using a prominent animal model of aspects of the disease, we here show using clinically relevant methodologies that very young, pre-pathological PDAPP mice, which overexpress mutant human amyloid precursor protein in the brain, exhibit two cryptic deficits that are normally undetected using standard methods of assessment. Despite learning a spatial memory task normally and displaying normal brain glucose uptake, they display faster forgetting after a long delay following performance to a criterion, together with a strong impairment of brain glucose uptake at the time of attempted memory retrieval. Preliminary observations suggest that these deficits, likely caused by an impairment in systems consolidation, could be rescued by immunotherapy with an anti-β-amyloid antibody. Our data suggest a biomarker strategy for the early detection of β-amyloid-related abnormalities.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsAntibodies, NeutralizingBiological TransportBiomarkersBrainBrain MappingDeoxyglucoseDisease Models, AnimalFemaleGene ExpressionGlucoseHumansMaze LearningMemory DisordersAmyloid beta-Protein PrecursorAntibodies, NeutralizingAPP protein, humanBiomarkersDeoxyglucoseGlucose

Identifiers

PMID27249364
PMCPMC4895343

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.